INTU
54
2
OKE
61
2
NEE
39
9
CRM
65
6
PX
56
3
GILD
55
5
ABT
54
4
MHK
25
5
SLB
41
2
ROST
60
3
PVH
58
5
PLD
35
5
BXP
39
5
VNO
46
6
CCI
30
2
ILMN
31
4
ROP
44
6
SWK
53
4
SBUX
29
-2
JNPR
59
3
INTU
54
2
OKE
61
2
NEE
39
9
CRM
65
6
PX
56
3
GILD
55
5
ABT
54
4
MHK
25
5
SLB
41
2
ROST
60
3
PVH
58
5
PLD
35
5
BXP
39
5
VNO
46
6
CCI
30
2
ILMN
31
4
ROP
44
6
SWK
53
4
SBUX
29
-2
JNPR
59
3
Financhill
Back

Sinovac Biotech 10K Form

Sell
48

SVA
Sinovac Biotech

Last Price:
$6.47
Seasonality Move:
13.44%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive SVA News And Ratings

See the #1 stock for the next 7 days that we like better than SVA

SVA Financial Statistics

Sales & Book Value

Annual Sales: $448.3M
Cash Flow: $0
Price / Cash Flow: 0
Annual Sales: $120.36
Price / Book: 0.05

Profitability

EPS (TTM): -1.31000
Net Income (TTM): $-124.7M
Gross Margin: $266.8M
Return on Equity: -1.05%
Return on Assets: -0.93%

Sinovac Biotech Earnings Forecast

Key Sinovac Biotech Financial Ratios

  • The Gross Profit Margin over the past 24 years for SVA is 59.51%.
  • The Selling, General & Administrative Expenses for SVA have been equal to 104.03% of Gross Profit Margin.
  • The Research & Development expenses have been 76.85% of Revenue.
  • The Interest Expense is -2.26% of Operating Income.
  • The Net Earning history of SVA is -22.29% of Total Revenues.
  • Per Share Earnings over the last 25 years have been positive in 11 years.

Sinovac Biotech Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: SVA
CUSIP: P8696W
Website: sinovac.com

Debt

Debt-to-Equity Ratio: 0.04
Current Ratio: 11.39
Quick Ratio: 11.22

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

SVA Technical Analysis vs Fundamental Analysis

Sell
48
Sinovac Biotech (SVA) is a Sell

Is Sinovac Biotech a Buy or a Sell?

  • Sinovac Biotech stock is rated a Sell
    The current Sinovac Biotech [SVA] share price is $6.47. The Score for SVA is 48, which is 4% below its historic median score of 50, and infers higher risk than normal.